Just one week into 2019, the new year got off to the proverbial roaring start for biopharma mergers and acquisitions…
Super UserJuly 8, 2019
Arlington Capital Partners (“Arlington” or the “Firm”), a Washington, D.C. area based private equity investment firm focused on government-regulated sectors,…
Super UserJuly 1, 2019
Dr. Marco Chacón sits down for a new episode of BioTalk to talk about his Founding of Paragon to its…
Super UserJuly 1, 2019
The University of Maryland, Baltimore plans an ambitious expansion of its BioPark, with a $200 million building that will nearly…
Super UserJuly 1, 2019
Sometimes a Eureka moment sparks a breakthrough in innovation; other times it’s a rush to solve a crisis plaguing society…
Super UserJuly 1, 2019
The days of Roche having an immunotherapy monopoly on the largest population of small-cell lung cancer patients appear numbered, following…
Super UserJuly 1, 2019
If biopharma firms want to get the most out of continuous manufacturing, they must rethink their viral safety strategies. Existing…
Super UserJuly 1, 2019
By Dr. Kurt Newman, CEO of Children’s National Health System We have come a long way in pediatric medicine, but…
Super UserJuly 1, 2019
Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene…
Super UserJuly 1, 2019